- In its phase 3 clinical trial for female adult Rett syndrome, Anavex 2-73 produced results that were both clinically and statistically significant.
- Anavex and its investors were not rewarded for these results because the company had not announced that changes had been made in the outcome measures.
- The changes that were made were very unlikely to have affected trial results.
- Despite this misstep, the future of Anavex remains bright because Anavex 2-73 is likely treating the root causes of a series of devastating and poorly treated neurological conditions and diseases.
For further details see:
Anavex 2-73 (Blarcamesine) And The Treatment Of Rett Syndrome: An Important Step Forward